Efficacy of Pharmacological Products Drive the Global Atopic Dermatitis Drugs Market at 4.77% of CAGR in 2019-2027

According to a new market research report published by Inkwood Research, the Global Atopic Dermatitis Drugs Market is anticipated to flourish at a CAGR of 4.77% throughout the forecasting years of 2019-2027.

“According to a new market research report published by Inkwood Research, the Global Atopic Dermatitis Drugs Market is anticipated to flourish at a CAGR of 4.77% throughout the forecasting years of 2019-2027.”

“Browse 24 market Data Tables and 18 Figures spread over 100 Pages, along with an in-depth TOC on Global Atopic Dermatitis Drugs Market forecast 2019-2027.”

Buy Now

Atopic dermatitis, also known as atopic eczema, is a widespread chronic inflammatory skin condition causing red, swollen, itchy skin lesions and rashes. Atopy refers to a genetic tendency to produce IgE antibodies and dermatitis means inflammation of the skin. The disease is most prevalent among the children, but can be effective on all ages and tends to grow severe by age. Several factors like low humidity, allergies, usage of harsh soaps and chemicals as well as cold weather potentially worsen atopic dermatitis.

Atopic dermatitis differs depending on the age of the patient. It can occur on knees, around the neck, elbows, arms, wrists and ankles, developing papules, which appears to be rashes. There is no cure found for atopic dermatitis, though few treatments and measure can reduce itching and prevent new outbreaks.

Pharmacological Products are Propelling the Global Atopic Dermatitis Drugs Market

The increasing usage of pharmacological products in developing countries have leveraged the growth of the market. Active pharmacological agents are capable of curing several skin diseases through percutaneous drug absorption and metabolism. Non-pharmacological skin treatment employs entire electromagnetic spectrums from various sources like lasers, X-rays, visible light and infrared light. In developing countries, the dermatology market generally witnesses low consumption of drugs to treat skin diseases. Hence, majority of the patients prefer alternative therapies like Ayurveda traditional medicines. However, with the rising disposable income and the developing healthcare infrastructure, the consumption of drugs to treat skin conditions is multiplying, fueling the market growth.

To know more about this report, request a free sample copy.

 Interleukin Inhibitor Drug Class Proceeds to Yield Highest CAGR

Biopharmaceutical medications are being developed to treat atopic dermatitis. In March 2017, a monoclonal antibody which targets Th2 cytokines interleukin (IL)-4 and IL-13, responsible for lowering inflammation and Dupilumab (Dupixent®) was validated for the treatment of atopic dermatitis. Randomized, double-blind, placebo-controlled phase 2 trial, employed interleukin-31 (IL-31) inhibitor Nemolizumab, suggesting to improve Pruritus in patients with moderate to severe atopic dermatitis. The result of the trial supports that IL-31, a cytokine comes in play by igniting T cells in the mechanism of the atopic dermatitis disease. It also depicts that targeting the increased level of protein can prove to be an effective strategy for the treatment. As a result, Interleukin Inhibitor class of drugs possess the fastest growth rate in the market.

Asia-pacific to Lead the Global Atopic Dermatitis Drugs Market

In the APAC region, there is a high prevalence of atopic dermatitis among the rest of the regions, due to the greater unmet needs for appropriate therapeutics compared to Europe. In countries like China, India and Malaysia, dermatitis is the most prevalent skin disease. The occurrence and the severity of the diseases vary according to the environmental and dietary factors specific to the region. One of the greatest challenges faced by vendors in the region is the lack of awareness among the patients. In APAC, the symptoms start before 5 years of age and can get severe by the age of 15. Consequently, this causes a delay in the treatment, worsening the disease in adulthood.

Some of the noteworthy players in the market are Allergan Plc, Aqua Pharmaceuticals, Astellas Pharma Inc., Bayer Ag, Bristol-Myers Squibb Company, Stiefel Laboratories Inc., Galderma Sa, Leo Pharma a/s, Meda Pharmaceuticals, Novartis Ag, Pfizer Inc., Sanofi Sa and Bausch Health Companies Inc.

The market is growing highly competitive, owing to factors such as rising demand for high-quality drugs for faster recovery from diabetes, low-to-moderate entry barriers to the budding companies and the presence of large and small firms. The existing established companies also share tough competition. In addition, the notable local players have a significant market share adding to the existing competition.


About Inkwood Research

Inkwood Research specializes in syndicated &customized research reports and consulting services. Market intelligence studies with relevant fact-based research are customized across industry verticals such as technology, automotive, chemicals, materials, healthcare, and energy; with an objective comprehension that acknowledges the business environments. Our geographical analysis comprises of North & South America, CEE, CIS, Middle East, Europe, Asia, and Africa.

Contact Us
+1 857-302-4704


Related Report: